To further address the mechanism underlying the induction of LSD1 deletion in preventing acquired resistance to anti‐PD1 immunotherapy, we conducted a thorough examination of the differentially expressed genes influenced by LSD1 inhibitor in both tumour cells and immune cells. The gene discussed is PDCD1; the disease is neoplasm.